Acarix AB
7AC
Company Profile
Business description
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96 percent certainty.
Contact
World Trade Center Malmo
Jungmansgatan 12
Malmo211 19
SWESector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2024
Employees
14
Stocks News & Analysis
stocks
What we think of the 3 big winners of the ASX 100
Exploring the ASX companies who dominated the market this year
stocks
Chart of the week: Where do our analysts see value?
This week's chart of the week looks at the under and overvalued sectors in the Australian market.
stocks
Attractive ASX opportunity with high yield
This REIT is undervalued after selloff despite interest-rate and vacancy headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,550.30 | 36.60 | -0.43% |
| CAC 40 | 7,409.57 | 11.37 | -0.15% |
| DAX 40 | 20,405.92 | 20.35 | -0.10% |
| Dow JONES (US) | 43,828.06 | 86.06 | -0.20% |
| FTSE 100 | 8,300.33 | 11.43 | -0.14% |
| HKSE | 19,971.24 | 425.81 | -2.09% |
| NASDAQ | 19,926.72 | 23.88 | 0.12% |
| Nikkei 225 | 39,470.44 | 378.70 | -0.95% |
| NZX 50 Index | 12,754.26 | 61.54 | 0.48% |
| S&P 500 | 6,051.09 | 0.16 | -0.00% |
| S&P/ASX 200 | 8,296.00 | 34.30 | -0.41% |
| SSE Composite Index | 3,391.88 | 69.62 | -2.01% |